Substance / Medication

Ipecac syrup

Overview

Active Ingredient
ipecac
RxNorm CUI
5975

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

65 trials linked to this intervention

65
Total Trials
6
Recruiting
21
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Ipecac syrup abuse, morbidity, and mortality: isn't it time to repeal its over-the-counter status?
Silber Tomas J · J Adolesc Health · 2005
PMID: 16109351Observational
Position paper update: ipecac syrup for gastrointestinal decontamination.
Höjer J, Troutman W G, Hoppu K et al. · Clin Toxicol (Phila) · 2013
PMID: 23406298Review
Guideline on the use of ipecac syrup in the out-of-hospital management of ingested poisons.
Manoguerra Anthony S, Cobaugh Daniel J, [object Object] · Clin Toxicol (Phila) · 2005
PMID: 15732439Review
Position paper: Ipecac syrup.
J Toxicol Clin Toxicol · 2004
PMID: 15214617Review
Ipecac syrup-induced emesis...no evidence of benefit.
Krenzelok Edward P · Clin Toxicol (Phila) · 2005
PMID: 15732440Other
Evaluation of the time frame for home ipecac syrup use when not kept in the home.
Garrison James, Shepherd Greene, Huddleston William L et al. · J Toxicol Clin Toxicol · 2003
PMID: 12807301Other
Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets: involvement of 5-hydroxytryptamine receptors.
Hasegawa Masayuki, Sasaki Toshinobu, Sadakane Koichi et al. · Jpn J Pharmacol · 2002
PMID: 12120752Preclinical
[Pharmacokinetics and tissue distribution of ipecac syrup].
Yamashita M, Yamashita M, Fujii Y · Chudoku Kenkyu · 2001
PMID: 11381462Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ipecac syrup (substance)
SNOMED CT
47937008
UMLS CUI
C0022046
RxNorm CUI
5975

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
65
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.